QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: GVP Module VIII Post-Authorisation Safety Studies

Test your understanding of the concepts covered by GVP Module VIII: Post-Authorisation Safety Studies Explained.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A company conducts a voluntary non-interventional study to quantify the incidence of a serious adverse outcome associated with an authorised product. What is the most appropriate interpretation?

It cannot be a PASS because no authority imposed it It is outside pharmacovigilance because it is voluntary It may be a PASS and remains subject to applicable PASS requirements It is automatically a clinical trial because it is prospective

Question 2 of 10 An observational study uses electronic health records, but its protocol requires investigators to assign patients to treatment groups before prescribing. What is the key regulatory implication?

The study remains non-interventional because electronic records are used The study remains non-interventional because it is labelled observational The protocol-directed treatment assignment may place the study outside the non-interventional framework The study is automatically exempt from pharmacovigilance requirements

Question 3 of 10 Which statement best describes the relationship between a safety signal and a PASS?

A safety signal is itself a completed PASS A PASS is required for every signal without further assessment A signal may provide the rationale for a PASS, while the PASS is the structured study designed to investigate a defined question A PASS can never be used to investigate a known safety concern

Question 4 of 10 Which feature is most important for making a PASS protocol a useful control document?

It uses technical terminology without stating the decision the study will inform It links the safety question to objectives, population, exposure, outcomes, methods, limitations and reporting arrangements It avoids documenting deviations to preserve flexibility It focuses only on the statistical analysis plan

Question 5 of 10 Why should a study's internal name not be used as its regulatory classification?

Internal names are prohibited under EU law Terms such as registry, observational study and real-world evidence study can describe activities with different regulatory purposes and designs Only competent authorities may name a study Study names determine whether data can be analysed

Question 6 of 10 Why should implementation of a risk-minimisation measure not be equated with its effectiveness?

Implementation data are always unreliable Delivery of a measure does not demonstrate that it changed knowledge, behaviour, clinical processes or outcomes Effectiveness can only be assessed in randomised clinical trials Risk-minimisation measures do not have measurable objectives

Question 7 of 10 Which statement best describes the relationship between a PASS and an RMP?

A PASS and an RMP are alternative names for the same document A PASS is a pharmacovigilance activity that may be included within the broader RMP framework Every PASS must be listed in the RMP before it can begin An RMP is limited to risk-minimisation measures and cannot include studies

Question 8 of 10 Which statement best explains why sophisticated statistical analysis cannot always compensate for weaknesses elsewhere in a PASS?

Statistical methods are irrelevant to PASS A weak regulatory question, poor data quality or inadequate exposure ascertainment may limit the evidence regardless of analytical sophistication Only descriptive analyses are allowed in PASS Statistical quality is determined solely by sample size

Question 9 of 10 Which example most clearly evaluates risk-minimisation effectiveness rather than merely implementation?

Recording that educational materials were distributed Counting the number of healthcare professionals who received a letter Assessing whether the intervention changed prescribing behaviour and reduced the targeted clinical outcome Documenting that the measure was included in the product information

Question 10 of 10 Which sequence best represents a controlled PASS lifecycle?

Study conduct, commercial launch, protocol, classification, final report Need or uncertainty, classification, objectives and protocol, conduct, analysis, reporting and regulatory follow-up Publication, signal closure, vendor selection, data collection and RMP creation Database selection, marketing decision, protocol deletion, analysis and registration

QPPV.com

Knowledge Assessment: GVP Module VIII Post-Authorisation Safety Studies

Cookie Settings